Reverse Syphilis Screening: ADPH Clinical Update

Satellite Conference and Live Webcast Thursday, June 9, 2011 8:00 - 9:30 a.m. Central Time

Produced by the Alabama Department of Public Health Video Communications and Distance Learning Division

Faculty

Mary G. McIntyre, MD, MPH
Medical Officer
Bureau of Communicable Disease
Alabama Department of Public Health

Objectives

- Discuss the reason for changes from the traditional to reverse sequence testing
- Review algorithm for the new reverse sequence syphilis screening

Objectives

- Describe the evaluation, management and treatment of persons based on the new reverse syphilis screening algorithm using scenarios developed
- Identify three reasons for discordant test results and the management of a person with a discordant test result
 - -Refer to scenarios

Paradigm Shift!

- 1980s
 - -FDA approves EIA for use as confirmatory test and in blood bank screening
- 2000
 - –UK Public Laboratory Guidelines:EIA "appropriate alternative" toVDRL/RPR + TPPA

Paradigm Shift!

- 2001
 - EIA cleared by FDA for clinical diagnostic use
- 2008
 - -EU Guidelines: EIA/TPPA recommended for screening, VDRL and RPR no longer recommended

Paradigm Shift!

- 2009
 - -CDC-APHL Report: Presents algorithm for screening with Trep EIA

Which Algorithm?

Traditional	Reverse Sequence
Detects active infection	Detects early primary and treated infection that may be missed by traditional screening
High rate of biologic false positives - Confirmation with treponemal test - Use of both tests results in a high positive predictive value	Nontreponemal test needed to detect active infection
Can miss early primary and treated infection	Ideally, EIAs and CIAs should have perfect specificity - EIAs and CIAs are nonspecific - Varies by risk of population

Why Switch to EIA/CIA?

- Automated
 - -High throughput
- · Low cost in high volume settings
- · Less lab occupational hazard
 - -Pipetting
- No false negatives due to prozone reaction

Why Switch to EIA/CIA?

- Objective results
- Some EIA/CIAs detect antibodies
 - Potentially useful for diagnosis of early syphilis

Diagnosis of Syphilis

- Treponema pallidum cannot be cultured
- Ideally, early syphilis would be diagnosed using direct detection methods
- Direct detection methods are not widely available

Diagnosis of Syphilis

- Direct detection methods can miss cases
- Most persons present without symptoms or signs
- Syphilis is usually diagnosed via serologic tests

Serologic Tests


- Nontreponemal
 - Venereal Disease Research Laboratory (VDRL) test
 - -Rapid Plasma Reagin (RPR) test
 - -Toluidine Red Unheated Serum Test (TRUST)

Serologic Tests


- Treponemal
 - Enzyme Immunoassays (EIAs)
 - Trep-Chek
 - Trep-Sure
 - Treponema pallidum article agglutination (TP-PA)

Serologic Tests

- Fluorescent treponemal antibody absorbed (FTA-ABS)
- Chemiluminescence Immunoassays (CIAs)
 - LIAISON
 - Architect




Reverse Sequence Algorithm





If incubating or primary syphilis is suspected, treat

Reverse Sequence Algorithm




Evaluate clinically, determine if treated in past, assess risk of infection, and treat per CDCs STD Treatment Guidelines if not previously treated






Scenarios Review



Syphilis EIA-POS VDRL-POS: Scenario 2 Management/ Exam/History Impression Treatment New syphilis **Exam findings** Treat based upon infection stage of the consistent with disease syphilis OR Examine and History of recent treat contacts exposure to an Monitor serologic infectious case response to AND No history treatment of treatment in Follow-up per the past protocol



Syphilis EIA-POS VDRL-POS: Scenario 4 Management/ Exam/History Impression Treatment No positive exam Possible •Treat based upon syphilis re-infection stage of the findings for syphilis disease No history of recent •Examine contacts symptoms/exposure to and treat based on primary or secondary results syphilis <u>AND</u> •Follow-up per No history of treatment protocol in the past •Monitor serologic response to treatment

Syphilis EIA-POS VDRL-NEG T-PA-POS: Scenario 1 Management/ Exam/History Impression Treatment Old treated •No treatment History of past syphilis treatment •No further <u>AND</u> follow-up No history of needed recent exposure or re-infection

Exam/History	Impression	Management/ Treatment
Exam findings consistent OR History of recent exposure to an infectious case OR History of serologic conversion	Syphilis infection present	Treat based upor stage of the disease Examine and treat contacts Follow-up per protocol No further follow up if repeat VDRL is negative

Syphilis EIA-POS VDRL-NEG T-PA-POS: Scenario 3		
Exam/History	Impression	Management/ Treatment
No history of past treatment AND No history of recent symptoms/ exposure or re-infection	Syphilis infection present	•Treat as Late Latent Syphilis •No further follow-up after treatment

Syphilis EIA-POS VDRL-NEC T-PA-NEG: Scenario 1			
Exam/History	Impression	Management / Treatment	
No exam findings consistent with syphilis AND No history of recent exposure to an infectious case	Old treated syphilis Possible false positive	No treatment No further follow-up needed	

T-PA-NEG: Scenario 2			
Exam/History	Impression	Management/ Treatment	
Exam findings consistent with syphilis OR History of recent exposure to an infectious case	Syphilis infection present	Treat based upon stage of the disease Examine and treat contacts Follow-up per protocol No further action if repeat VDRL and TP-PA is negative	

What Are the Reasons for Discordant Test Results?

- False-positive EIA/CIA
- · Treated syphilis
- Early primary syphilis

Challenges/Limitations of EIA/CIA

- Cannot distinguish between active and old disease
- Studies to compare test performance with other serologic tests are lacking
- Studies evaluating performance of EIA/CIA to detect IgM antibodies in early syphilis are lacking

Challenges/Limitations of EIA/CIA

 Confusion about management of patients with discordant serology ***

Conclusions

- EIA/CIA have high sensitivity but lower specificity
- All reactive EIA/CIAs must be reflexly tested with a quantitative RPR
 - -Confirm reactive EIA/CIA
 - -Detect active infection

Conclusions

- Test performance varies by prevalence in the population and all discordant results must be confirmed with a treponemal test
- Confirmatory test recommended by CDC is TP-PA not FTA-ABS

Contact Information

Mary G. McIntyre, MD, MPH

Email: mary.mcintyre@adph.state.al.us

Phone: 334 - 206 - 5100 334 - 206 - 5325